🚀 VC round data is live in beta, check it out!
Kodiak Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Kodiak Sciences and similar public comparables like Kalbe Farma, Celldex Therapeutics, Hisamitsu Pharmaceutical, Disc Medicine and more.
Kodiak Sciences Overview
About Kodiak Sciences
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Founded
2009
HQ
Employees
109
Website
Sectors
Financials (LTM)
EV
$2B
Kodiak Sciences Financials
Kodiak Sciences reported last 12-month revenue of — and negative EBITDA of ($228M).
In the same LTM period, Kodiak Sciences generated — in gross profit, ($228M) in EBITDA losses, and had net loss of ($233M).
Revenue (LTM)
Kodiak Sciences P&L
In the most recent fiscal year, Kodiak Sciences reported revenue of — and EBITDA of ($204M).
Kodiak Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($228M) | XXX | ($204M) | XXX | XXX | XXX |
| Net Profit | ($233M) | XXX | ($230M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Kodiak Sciences Stock Performance
Kodiak Sciences has current market cap of $3B, and enterprise value of $2B.
Market Cap Evolution
Kodiak Sciences' stock price is $42.36.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $3B | 1.3% | XXX | XXX | XXX | $-3.72 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialKodiak Sciences Valuation Multiples
Kodiak Sciences trades at (10.8x) EV/EBITDA.
EV / Revenue (LTM)
Kodiak Sciences Financial Valuation Multiples
As of April 11, 2026, Kodiak Sciences has market cap of $3B and EV of $2B.
Equity research analysts estimate Kodiak Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Kodiak Sciences has a P/E ratio of (11.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/EBITDA | (10.8x) | XXX | (12.1x) | XXX | XXX | XXX |
| EV/EBIT | (10.4x) | XXX | (10.5x) | XXX | XXX | XXX |
| P/E | (11.3x) | XXX | (11.4x) | XXX | XXX | XXX |
| EV/FCF | (15.7x) | XXX | (18.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Kodiak Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Kodiak Sciences Margins & Growth Rates
Kodiak Sciences' revenue in the last fiscal year grew by —.
Kodiak Sciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Kodiak Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 2% | XXX | 16% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Kodiak Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kalbe Farma | XXX | XXX | XXX | XXX | XXX | XXX |
| Celldex Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Hisamitsu Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Sinocelltech Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kodiak Sciences M&A Activity
Kodiak Sciences acquired XXX companies to date.
Last acquisition by Kodiak Sciences was on XXXXXXXX, XXXXX. Kodiak Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Kodiak Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialKodiak Sciences Investment Activity
Kodiak Sciences invested in XXX companies to date.
Kodiak Sciences made its latest investment on XXXXXXXX, XXXXX. Kodiak Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Kodiak Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Kodiak Sciences
| When was Kodiak Sciences founded? | Kodiak Sciences was founded in 2009. |
| Where is Kodiak Sciences headquartered? | Kodiak Sciences is headquartered in United States. |
| How many employees does Kodiak Sciences have? | As of today, Kodiak Sciences has over 109 employees. |
| Who is the CEO of Kodiak Sciences? | Kodiak Sciences' CEO is Victor Perlroth. |
| Is Kodiak Sciences publicly listed? | Yes, Kodiak Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Kodiak Sciences? | Kodiak Sciences trades under KOD ticker. |
| When did Kodiak Sciences go public? | Kodiak Sciences went public in 2018. |
| Who are competitors of Kodiak Sciences? | Kodiak Sciences main competitors are Kalbe Farma, Celldex Therapeutics, Hisamitsu Pharmaceutical, Disc Medicine. |
| What is the current market cap of Kodiak Sciences? | Kodiak Sciences' current market cap is $3B. |
| Is Kodiak Sciences profitable? | No, Kodiak Sciences is not profitable. |
| What is the current EBITDA of Kodiak Sciences? | Kodiak Sciences has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Kodiak Sciences? | Current EBITDA multiple of Kodiak Sciences is (10.8x). |
| What is the current FCF of Kodiak Sciences? | Kodiak Sciences' last 12 months FCF is ($157M). |
| What is the current EV/FCF multiple of Kodiak Sciences? | Current FCF multiple of Kodiak Sciences is (15.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.